Literature DB >> 10544300

Estrogen in the etiopathogenesis of BPH.

W E Farnsworth1.   

Abstract

BACKGROUND: While the androgen-dependence of the prostate gland has long been accepted, the participation of estrogen, mediated via the stroma in the elicitation of benign prostatic hyperplasia (BPH), has only recently been recognized. Its mode of action is still uncertain.
METHODS: This review first outlines the regulation of gene expression via hormones, growth factors, and other ligands in the coordination of cell growth, differentiation, and function. Focus is next directed to factors particularly involved in phosphorylation of estrogen receptors. Then, the access of sex steroids, especially of estrogen to the cell and to the transduction machinery, is described, preparatory to examining the hypotheses by which this access causes the process of BPH to occur.
RESULTS: It becomes clear that the necessary phosphorylative activities which transmit signals to nuclear receptors and thence transcription of target genes can be performed by steroids or mimicked by proxy molecules and by cross-talk between discrete pathways. The character and concentration of the available estrogen are determined by the extent of its biosynthesis, its penetration of the cell, and its subsequent metabolism. In addition, the estrogen affects its own access through stimulation of facilitating peptide hormones, prolactin, and sex hormone-binding globulin. Finally, the induction of BPH is shown to be determined by the androgen/estrogen ratio and the change in stromal/epithelial balance accompanying aging.
CONCLUSIONS: Despite a growing knowledge of hormone levels, metabolism, and activities in the prostate, and the variety of processes and factors they affect, our explanation of BPH is still fanciful. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10544300     DOI: 10.1002/(sici)1097-0045(19991201)41:4<263::aid-pros7>3.0.co;2-0

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

Authors:  Rui Yang; Yu-Xia Ma; Lin-Feng Chen; Ying Zhou; Zhan-Po Yang; Yan Zhu; Xiao-Ling Du; Jian-Dang Shi; Hong-Shun Ma; Ju Zhang
Journal:  Asian J Androl       Date:  2010-05-17       Impact factor: 3.285

Review 2.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

3.  Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis.

Authors:  Yang Yang; Jindong Sheng; Shuai Hu; Yun Cui; Jing Xiao; Wei Yu; Jing Peng; Wenke Han; Qun He; Yu Fan; Yuanjie Niu; Jun Lin; Ye Tian; Chawnshang Chang; Shuyuan Yeh; Jie Jin
Journal:  Cell Death Dis       Date:  2022-06-07       Impact factor: 9.685

4.  Distinct function of estrogen receptor α in smooth muscle and fibroblast cells in prostate development.

Authors:  Spencer Vitkus; Chiuan-Ren Yeh; Hsiu-Hsia Lin; Iawen Hsu; Jiangzhou Yu; Ming Chen; Shuyuan Yeh
Journal:  Mol Endocrinol       Date:  2012-11-30

5.  Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats.

Authors:  Ying Zhou; Xiang-Qian Xiao; Lin-Feng Chen; Rui Yang; Jian-Dang Shi; Xiao-Ling Du; Helmut Klocker; Irwin Park; Chung Lee; Ju Zhang
Journal:  Asian J Androl       Date:  2009-06-01       Impact factor: 3.285

Review 6.  Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.

Authors:  A Bardin; N Boulle; G Lazennec; F Vignon; P Pujol
Journal:  Endocr Relat Cancer       Date:  2004-09       Impact factor: 5.678

7.  Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation.

Authors:  Lamia Benbrahim-Tallaa; Mukta M Webber; Michael P Waalkes
Journal:  Environ Health Perspect       Date:  2005-09       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.